Modificaciones de la fibrosis hepática valorada mediante elastometría transitoria en pacientes con respuesta viral sostenida tras el tratamiento de la hepatitis C en pacientes monoinfectados (VHC) y coinfectados (VHC – VIH)
- López Zúñiga, Miguel Ángel
- Castillo Fernández, Alba María
- Elisabeth de Jesús, Samantha
- Sola García, Miguel
- Pasquau Liaño, Juan
- Moreno Toro, Noelia
- López Ruz, Miguel Ángel
ISSN: 0365-7965
Year of publication: 2017
Tome: 102
Issue: 800
Pages: 18-22
Type: Article
More publications in: Actualidad médica
Abstract
Introduction: It has been shown that patients infected with hepatitis C virus (HCV), who have already developed a significant degree of fibrosis, are able to reduce that degree of fibrosis by achieving a sustained virological response (SVR) after treatment with Pegylated interferon (PEG-IFN) and ribavirin (RBV). Objective: To evaluate the modification of fibrosis, measured by transient elastometry, after HCV eradication in patients treated with PEG-IFN and RBV, with Boceprevir / Telaprevir, and with direct acting agents (AAD) and to determine the association between the variation in fibrosis and the degree of pre-treatment fibrosis in both monoinfected (HCV) and coinfected (HIV / HCV) patients. Methods: This work is a prospective observational study. 50 patients were studied and their degree of fibrosis before and after treatment was evaluated. Results: 45.2% of patients decreased their fibrosis, with a mean decrease of 9.45kPa and 45.2% decreased at least one stage on the Metavir scale. There was an association between a lower degree of fibrosis before treatment and a greater decrease in fibrosis (p <0.001). However, no differences were observed between monoinfection and HIV coinfection (p = 0.713). No significant association was detected between the three types of treatments and the modification of fibrosis (p = 0.445). Conclusions: In our study, SVR in patients with chronic HCV hepatitis facilitates the reduction of fibrosis produced by the disease, both in monoinfected patients and in coinfected patients (HIV / HCV), regardless of the treatment used.
Bibliographic References
- Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30-6.10.1111/ liv.12576
- Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6-9.10.1016/j.jhep.2005.11.004
- Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054- 8.10.1002/hep.510300409
- Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013;58(6):1104-12.10.1016/j.jhep.2013.01.042
- Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34(5):748-55.http://dx.doi.org/10.1016/ S0168-8278(01)00062-9
- Casado JL, Quereda C, Moreno A, Perez-Elias MJ, Marti-Belda P, Moreno S. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. J Viral Hepat. 2013;20(12):829- 37.10.1111/jvh.12108
- Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-47.10.1016/j.jhep.2008.02.008
- Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive
- Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-9.10.1086/321909
- Highleyman L. Liver fibrosis improves after successful treatment for hepatitis C 2015 [Available from: http://www. aidsmap.com/Liver-fibrosis-improves-after-successfultreatment-for-hepatitis-C/page/3015981/.
- Lissen E, Clumeck N, Sola R, Mendes-Correa M, Montaner J, Nelson M, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS. 2006;20(17):2175-81.10.1097/01.aids.0000247584.46567.64
- Macias J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother. 2010;65(10):2204-11.10.1093/jac/dkq272
- Macias J, Rivero A, Cifuentes C, Camacho A, Neukam K, RiveroJuarez A, et al. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. Enferm Infecc Microbiol Clin. 2013;31(7):424-9.10.1016/j.eimc.2012.12.004
- Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399-403.10.7326/0003-4819-149-6- 200809160-00006
- Mandorfer M, Schwabl P, Steiner S, Reiberger T, PeckRadosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int. 2016;10(3):424-35.10.1007/s12072- 015-9691-4
- model. Hepatology. 2002;36(4 Pt 1):986-92.10.1053/ jhep.2002.36128
- Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int. 2016;36(12):1765-73.10.1111/ liv.13156
- Pineda JA, Recio E, Camacho A, Macias J, Almodovar C, Gonzalez-Serrano M, et al. Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C viruscoinfected patients with cirrhosis. J Acquir Immune Defic Syndr. 2009;51(4):445-9.10.1097/QAI.0b013e3181acb675
- Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis. 2012;32(2):103-13.10.1055/s-0032-1316473
- Robic MA, Procopet B, Metivier S, Peron JM, Selves J, Vinel JP, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011;55(5):1017-24.10.1016/j. jhep.2011.01.051
- Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45(5):1290-7.10.1002/hep.21665
- Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995- 2004. Hepatology. 2008;47(4):1128-35.10.1002/hep.22165